Business Context and Reporting Period
This Form 6-K filing by CollPlant Biotechnologies Ltd. covers the month of July 2026. The report details a private placement offering entered into on June 29, 2026, with an expected closing date of July 1, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2.6 million.
- Securities Issued: 7,647,061 ordinary shares or pre-funded warrants.
- Purchase Price: $0.34 per ordinary share (or $0.3399 per pre-funded warrant) including accompanying warrants.
- Warrants Issued:
- Series A Warrants: 7,647,061 shares, exercise price $0.34, 2-year term.
- Series B Warrants: 15,294,122 shares, exercise price $0.34, 5-year term.
- Pre-Funded Warrants: Exercise price $0.0001, immediately exercisable.
- Placement Agent Fees: 7.0% of gross proceeds (3.5% for existing shareholders), 1.0% management fee, $35,000 expense allowance, and $50,000 legal fees.
- Placement Agent Warrants: 458,824 shares (6.0% of aggregate shares placed), exercise price $0.425.
Material Changes and Use of Proceeds
The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the period. The primary material change is the capital raise. The Company intends to use net proceeds for:
- General corporate purposes and working capital.
- Funding research and development programs.
- Evaluating strategic business combinations, including acquisitions and joint ventures.
Guidance, Outlook, and Restrictions
Management commentary is limited to the intended use of proceeds. The filing outlines significant transactional restrictions:
- Lock-up Period: The Company is restricted from issuing new ordinary shares or filing registration statements for 90 days following the Effective Date.
- Variable Rate Transaction Ban: Prohibited for one year following the Effective Date.
- Participation Rights: Purchasers have a right to participate in subsequent financings for 24 months.
- Ownership Caps: Warrant exercise is limited if the holder would beneficially own more than 4.99% (or up to 24.99% at election) of outstanding shares.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received versus the expected $2.6 million.
- Confirm the effective date of the resale registration statement (required within 60-90 days of the agreement).
- Monitor the Company's cash burn rate to assess if the $2.6 million net proceeds are sufficient to fund R&D and operations until the next financing.
- Review the impact of the 90-day lock-up on the Company's ability to raise additional capital if needed.
- Check for shareholder approval status required for the exercise of Series A and Series B warrants.